Key points are not available for this paper at this time.
Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.
Building similarity graph...
Analyzing shared references across papers
Loading...
Journal of Clinical Oncology
Vita-Salute San Raffaele University
National Health Service
University of New Brunswick
Add This Paper to Your Research Feed
Any time a new paper drops it will be there.
Ghia et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: